《RNA干擾:從生物學到臨床應用(英文導讀版)》內容簡介：從最開始RNA干擾還只是注射到線蟲里的一個人工合成物，到2006年Fire和Mello因此獲得諾貝爾獎，再到如今的臨床試驗，RNA干擾領域的發展可謂日新月異。這本書匯集該領域的多位研究專家，提供了最新的科學知識和實驗方案，并將這一生物學分支領域從核酸化學擴展到藥理學和信號轉導通路的調控。《RNA干擾:從生物學到臨床應用(英文導讀版)》分為三部分，闡述了RNA干擾的生理機制、RNA干擾的實驗室研究和siRNA導入、RNA干擾的臨床應用。RNA干擾：從生物學到臨床應用（英文導讀版）專業權威．通過回顧RNA干擾領域的研究進展、提供具體的實驗方案和啟發新思路，旨在對該領域起到推動作用。
《RNA干擾:從生物學到臨床應用(英文導讀版)》秉承Springer《分子生物學方法》系列叢書的一貫風格，闡述明晰、便于使用，各章包括內容簡介，必備材料與試劑的清單，易于操作的實驗室方案、疑難問題的注意事項和易犯失誤的避免。
《RNA干擾：從生物學到臨床應用（導讀版）》特點：《RNA干擾：從生物學到臨床應用（導讀版）》為Springer經典實驗室指南系列《分子生物學方法》（Methods in Mo/ecu/ar Bio/ogy）的分卷。重點闡述RNA干擾相關藥物使用的臨床前期及臨床相關實際問題。
Wei-Ping Min稤epartments of Surgery,Microbiology and Immunology,and Pathology,University of Western Ontario,London,ON,CanadaThomas Ichim稭ediStem Laboratories Inc.,San Diego,CA,USA Achim Aigner稤epartment of Pharmacology and Toxicology,School of Medicine,Philipps-University,Marburg,GermanyYukio Akaneya稤ivision of Neurophysiology,Department of Neuroscience,Osaka University Graduate School of Medicine,Osaka,JapanMiyuki Azuma稤epartment of Molecular Immunology,Graduate School,Tokyo Medical and Dental University,Tokyo,JapanOleksandr Baturevych稤epartment of Pharmacology,Toxicology and Virology,MDRNA Inc.,Bothell,WA,USANicolas Beaudet稤epartment of Physiology and Biophysics,Faculty of Medicine and Health Sciences,Universit
前言
撰稿人
第一部分 RNA干擾的生理機制
1 RNA干擾的內源性抗病毒機制:一個比較生物學觀點 Abubaker M.E.Sidahmed,and Bruce Wilkie
2 在哺乳動物細胞中,siRNA監控先天性免疫的募集 Michael P.Gantier,and Bryan R.G.Williams
3 病毒感染細胞中microRNA和非編碼RNA的研究現狀 Dominique L.Ouellet,and Patrick Provost
4 RNA干擾引發的等位基因特異性沉默 Hirohiko Hohjoh
5 考慮選擇性剪切的siRNA計算機設計 Young J.Kim
6 生物信息學方法選擇和優化siRNA Pirkko Muhonen,and Harry Holthofer
7 單個載體上共表達多個shRNA優化基因沉默 Yasuhito Ishigaki,Akihiro Nagao,and Tsukasa Matsunaga
8 應用表達多基因單位策略下調HIV-1 Jane Zhang and John J.Rossi
9 基于靶位點的可接近性設計最佳siRNA Ivo L.Hofacker and Hakim Tafer
10 2′-氧烷基siRNA的化學合成 Joachim W.Engels,Dalibor Odadzic,Romualdas Smicius,and Jens Haas
第二部分 RNA干擾的實驗室研究和siRNA導入
11 靶向樹突狀細胞的siRNA特異性導入系統 Xiufen Zheng,Costin Vladau,Aminah Shunner,and Wei-Ping Min
12 流體力學導入的實驗方案 Piotr G.Rychahou and B.Mark Evers
13 在固體表面進行siRNA反式轉染的新方法 Satoshi Fujita,Kota Takano,Eiji Ota,Takuma Sano,Tomohiro Yoshikawa,Masato Miyake,and Jun Miyake
14 神經退行性疾病中,運用非病毒載體導入siRNA進行基因沉默 Satya Prakash,Meenakshi Malhotra,and Venkatesh Rengaswamy
15 運用siRNA發現新的癌癥信號通路 Jin-Mei Lai,Chi-Ying F.Huang,and Chang-Han Chen
16 癌癥研究中,運用生物可降解的聚合物介導sh/siRNA導入Dhananjay J.Jere and Chong-Su Cho
17 用TatU1A向細胞導入siRNA和光誘導RNA干擾 Tamaki Endoh and Takashi Ohtsuki
18 體內外聚乙烯亞胺(PEI)/siRNA介導的基因沉默 Sabrina Höbel and Achim Aigner
19 多發性骨髓瘤細胞系siRNA的轉染 Jose L.R.Brito,Nicola Brown,and Gareth J.Morgan
第三部分 臨床應用
20 應用RNA干擾在腦內進行治療的新方法 Yukio Akaneya
21 癌癥免疫療法中受抑制的RNA分子 Chih-Ping Mao and T.-C.Wu
22 應用siRNA避免組織損傷 Zhu-Xu Zhang,Marianne E.Beduhn,Xiufen Zheng,Wei-Ping Min,and Anthony M.Jevnikar
23 應用基因沉默避免免疫排斥 Xusheng Zhang,Mu Li,and Wei-Ping Min
24 在過敏性皮膚病中,局部運用siRNA靶定皮膚樹突狀細胞 Miyuki Azuma,Patcharee Ritprajak,and Masaaki Hashiguchi
25 直接用siRNA進行體內疼痛研究 Philippe Sarret,Louis Doré-Savard,and Nicolas Beaudet
26 RNA干擾作為治療流感的備用方法 Shaguna Seth,Michael V.Templin,Gregory Severson,and Oleksandr Baturevych
27 評估卵巢癌基因沉默治療方案中的靶標:體內和體外的方法 Anastasia Malek and Oleg Tchernitsa
索引
Chapter 1
Endogenous Antiviral Mechanisms of RNA Interference: A Comparative Biology Perspective
Abubaker M.E. Sidahmed and Bruce Wilkie
Abstrat
RNA interference (RNAi) is a natural process that occurs in many organisms ranging from plants to mammals. In this process, double-stranded RNA or hairpin RNA is cleaved by a RNaseIII-type enzyme called Dicer into small interfering RNA duplex. This then directs sequence-specific, homology-dependent, posttranscriptional gene silencing by binding to its complementary RNA and triggering its elimination through degradation or by inducing translational inhibition. In plants, worms, and insects, RNAi is a strong antiviral defense mechanism. Although, at present, it is unclear whether RNA silencing naturally restricts viral infection in vertebrates, there are signs that this is certainly the case. In a relatively short period, RNAi has progressed to become an important experimental tool both in vitro and in vivo for the analysis of gene function and target validation in mammalian systems. In addition, RNA silencing has subsequently been found to be involved in translational repression, transcriptional inhibition, and DNA degradation. In this article we review the literature in this field, which may open doors to the many uses to which this important technology is being put, including the potential of RNAi as a therapeutic strategy for gene regulation to modulate host-pathogen interactions.
Key words: RNA interference, Dicer, Transposons, siRNA, miRNA, Antiviral, Silencing, Suppressors, Quelling
1. Discovery and Historical Overview
RNA silencing is a broad term that has been used to describe RNA interference (RNAi) in animals, posttranscriptional gene silencing in plants, and quelling in fungi, which are all phenotypically different but mechanistically similar forms of RNAi (1).RNAi is a natural process in which double-stranded RNA (dsRNA) or hairpin RNA is cleaved by RNaseIII-type enzyme called Dicer into small interfering RNA (siRNA) duplex of 21-26 nucleotides, which then direct sequence-specific, homology-dependent, posttranscriptional
Wei-Ping Min and Thomas Ichim (eds.), RNA Interference, Methods in Molecular Biology, vol. 623, DOI 10.1007/978-1-60761-588-0_1, . Springer Science+Business Media, LLC 2010
Sidahmed and Wilkie
gene silencing by binding to its complementary RNA and triggering its elimination through degradation or by inducing translational inhibition (2, 3). RNA silencing is an evolutionarily ancient RNA surveillance mechanism, conserved among eukaryotes as a natural defense mechanism to protect the genome against invasion by mobile genetic elements, such as viruses, transposons, and possibly other highly repetitive genomic sequence and also to orchestrate the function of developmental programs in eukaryotic organisms (1, 2). Declaration of RNAi in 2002 as a “breakthrough” by the journal Science (4) encouraged scientists to revise their vision of cell biology and cell evolution, and the discovery of RNAi resulted in the Nobel Prize for Physiology or Medicine, being awarded to Andrew Fire and Craig Mello in 2006.
The discovery of RNAi followed observations in the late 1980s of transcriptional inhibition by antisense RNA expressed in transgenic plants (5), during a search for transgenic petunia flowers that were expected to be a more intense color of purple. In an attempt to alter flower colors in petunias, Jorgensen and colleagues (6) sought to upregulate the activity of the chalcone sythase (chsA) enzyme, which is involved in the production of anthocyanin pigments. They introduced additional copies of this gene. The overexpressed gene was expected to result in darker flowers in transgenic petunia, but instead it produced less pigmented, fully or partially white flowers, demonstrating that the activity of chsA had been significantly decreased. Actually, both the endogenous genes and the transgenes were downregulated in the white flowers. Surprisingly, the loss of cytosolic chsA mRNA was not linked with reduced transcription as tested by run-on transcription assays in isolated nuclei. Further investigation of the phenomenon in plants indicated that the downregulation was due to posttranscriptional inhibition of gene expression by an increased rate of mRNA degradation (6). Jorgensen invented the term “co-suppression of gene expression” to describe the elimination of mRNA of both the endogenous gene and the trans-gene, but the molecular mechanism remained unclear (6).
Other laboratories around the same time reported that the introduction of the transcribing sense gene could downregulate the expression of homologous endogenous genes (6, 7). A homology-dependent gene silencing phenomenon termed “quelling” was noted in the fungus Neurospora crassa (8). Quelling was recognized during attempts to increase the production of orange pigment expressed by the gene al1 of N. crassa (8). Wild-type N. crassa was transformed with a plasmid containing a 1.5 kb fragment of the coding region of the al1 gene. Some transformants were stably quelled and showed albino phenotypes. In these al1-quelled fungi, the amount of native mRNA was highly reduced while that of unspliced al1 mRNA was similar to the wild-type fungi. This indicated that quelling, but not the
Endogenous Antiviral Mechanisms of RNA Interference rate of transcription, affected the level of mature mRNA in a homology-dependent manner.
Shortly thereafter, plant virologists conducting experiments to improve plant resistance to viral infection made a similar, unexpected observation. While it was documented that plants produced proteins that mediated virus-specific enhancement of tolerance or resistance to viral infection, a surprising finding was that short, noncoding regions of viral RNA sequences carried by plants provided the same degree of protection. It was concluded that viral RNA produced by transgenes could also inhibit viral accumulation (9). Homology-dependent RNA elimination was also noticed to occur during an increase in viral genome of infected plants (10). Ratcliff et al. (11) described a reverse experiment, in which short sequences of plant genes were introduced into viruses and the targeted gene was suppressed in an infected plant. Viruses can be the source, the target, or both for silencing. This phenomenon was named “virus-induced gene silencing” (VIGS), and the whole setofsimilarphenomenawascollectivelynamedposttranscriptional gene silencing (11).
Not long after these observations in plants, investigators searched for homology-dependent RNA elimination phenomena in other organisms (12, 13). The phenomenon of RNAi first came to light after the discovery by Andrew Fire et al. in 1998 of a potent gene silencing effect, which occurred after injecting purified dsRNA directly into adult Caenorhabditis elegans (2). The injected dsRNA corresponded to a 742 nucleotide segment of the unc22 gene. This gene encodes nonessential but abundant myofilamentmuscleprotein.Theinvestigatorsobservedthatneither mRNA nor antisense RNA injections had an effect on production of this protein, but dsRNA successfully silenced the targeted gene. A decrease in unc22 activity is associated with severe twitching phenotype, and the injected animal as expected showed a very weak twitching phenotype, whereas the progeny nematodes showed strong twitching. The investigators then showed similar loss-of-function knockouts could be generated in a sequence-specific manner, using dsRNA corresponding to four other C. elegans genes, and they coined the term RNAi.
The Fire et al. discovery was particularly important because it was the first recognition of the causative agent of what was until then an unexplained phenomenon. RNAi can be initiated in C. elegans by injecting dsRNA into the nematodes (2), soaking them in a solution of dsRNA (14), feeding the worms bacteria that express dsRNA (15), and using transgenes that express dsRNA in vivo (16). This very potent method for knocking out genes required only catalytic amounts of dsRNA to silence gene expression. The silencing was not only in gut and other somatic cells, but also spread through the germ line to several subsequent generations (14). Similar silencing was soon confirmed in plants (17),
Sidahmed and Wilkie
trypanosomes (18), flies (19) and many other invertebrates and vertebrates. In parallel, it was determined that dsRNA molecules could specifically downregulate gene expression in C. elegans (2).
Subsequent genome screening lead to identification of small temporal RNA (stRNA) molecules that were similar to the siRNA in size, but in contrast to the siRNAs, stRNA were single-stranded and paired with genetically defined target mRNA sequences that were only partly complementary to the stRNA (20). Particularly, stRNAs lin-4 and let-7 were determined to bind with the 3￠noncoding regions of target lin-14 and lin-41 mRNAs, respectively, leading to reduction in mRNA-encoded protein accumulation. TheseobservationsencouragedinvestigatorstolookforstRNA-like molecules in different organisms, leading to the identification of hundreds of highly conserved RNA molecules with stRNA-like structural properties (21). These small RNAs are termed micro RNAs (miRNAs). They are produced from transcript that folds to stem-loop precursor molecules first in the nucleus by the RNA III enzyme Dorsha and then in the cytosol by Dicer, and they are present in almost every tissue of every animal investigated (22). Thus, the RNAi pathway guides two distinct RNA classes, double-stranded siRNA and single-stranded miRNA, to the cytosolic RISC complex, which brings them to their target molecules.
2. The Molecular Mechanism of RNA Interference
RNAi is a natural process of gene silencing that occurs in many organisms ranging from plants to mammals. RNAi was observed first by a plant scientist in the late 1980s, but the molecular basis of its mechanism remained unknown until the late 1990s, when research using the C. elegans nematode showed that RNAi is an evolutionarily conserved gene-silencing mechanism (2). Sequence-specific posttranscriptional RNAi gene silencing by double-stranded RNA is conserved in a wide range of organisms: plants (Neurospora), insect (Drosophila), nematodes (C. elegans), and mammals. This process is part of the normal defense mechanism against viruses and the mobilization of transposable genetic elements (2, 3). Although first discovered as a response to experimentally introduced RNA initiator, it is now known that RNAi and related pathways regulate gene expression at both transcriptional and posttranscriptional levels. The key steps in RNAi underlie several gene regulatory mechanisms that include downregulation of the expression of endogenous genes, direct transcriptional gene silencing and alteration of chromatin structure to promote kinetochore function, and chromosome segregation and direct elimination of DNA from somatic nclei in tetrahymena (23).
3. Intrinsic Antiviral Defense Mechanism of RNAi
3.1. Antiviral RNA Silencing in Mammals
Endogenous Antiviral Mechanisms of RNA Interference
The dsRNAs, generated by replicating viruses, integrated transposons, or one of the recently discovered classes of regulatory noncoding miRNAs, are processed into short dsRNAs (20). These short RNAs generate a flow of molecular and biochemical events involving a cytoplasmic ribonuclease III (RNase III)-like enzyme, known as Dicer, and a multi-subunit ribonucleoprotein complex called RNA-induced silencing complex (RISC). The antisense (guide) strand of the dsRNA directs the endonuclease activity of RISC to the homologous (target) site on the mRNAs, leading to its degradation and posttranscriptional gene silencing. The naturally occurring miRNAs are synthesized in large precursor forms in the nucleus. An RNA III enzyme called Drosha mediates the processing of the primary miRNA transcripts into pre-miRNA (70-80 mers), which are then exported via the exportin-5 receptor to the cytoplasm (24). In the cytoplasm, Dicer cleaves dsRNA, whether derived from endogenous miRNA or from replicating viruses, into small RNA duplexes of 19-25 base pairs (bp). These have characteristic 3￠-dinucleotide overhangs that allow them to be recognized by RNAi enzymatic machinery, leading to degradation of target mRNA (25). Dicer works with a small dsRNA-binding protein, R2D2, to pass off the siRNA to the RISC, which has the splicing protein Argonaute 2 (Ago2). Argonaute cleaves the target mRNA between bases 10 and 11 in relation to the 5￠-end of the antisense siRNA strand (26). The siRNA duplex is loaded into the RISC, whereupon an ATP-dependent helicase (Ago2) unwinds the duplex, allowing the release of “passenger” strand and leading to an activated form of RISC with a single-stranded “guide” RNA molecule (27, 28). The extent of complementarities between the guide RNA strand and the target mRNA decides whether mRNA silencing is achieved by site-specific cleavage of the mRNA in the region of the siRNA- mRNA duplex (29) or through an miRNA-like mechanism of translational repression (30). For siRNA-mediated silencing, the cleavage products are released and degraded, leaving the disengaged RISC complex to further survey the mRNA pool.
新書資訊